Finally Time To Cut Your Stake? Goldman Sachs Downgrades Eli Lilly (NYSE:LLY) Shares

January 17, 2018 - By mmahotstuff

 Finally Time To Cut Your Stake? Goldman Sachs Downgrades Eli Lilly (NYSE:LLY) Shares

Investors sentiment decreased to 0.89 in 2017 Q3. Its down 0.01, from 0.9 in 2017Q2. It fall, as 66 investors sold Eli Lilly and Company shares while 386 reduced holdings. 79 funds opened positions while 325 raised stakes. 827.83 million shares or 0.59% more from 823.00 million shares in 2017Q2 were reported.

Pinnacle Finance Prns invested in 37,083 shares. Moreover, Optimum Inv Advisors has 0.22% invested in Eli Lilly and Company (NYSE:LLY) for 7,560 shares. Amer Mgmt holds 300 shares. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 993,282 shares. Winslow Mngmt Ltd has 1.76% invested in Eli Lilly and Company (NYSE:LLY) for 3.81M shares. Mitsubishi Ufj Tru & has invested 0.36% in Eli Lilly and Company (NYSE:LLY). Pinebridge Investments Lp has invested 0.27% of its portfolio in Eli Lilly and Company (NYSE:LLY). Bancorpsouth Inc accumulated 2,727 shares. Cornerstone Inv Prtnrs Limited Liability Corporation holds 0.05% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 27,278 shares. Moreover, Dimensional Fund Advisors Lp has 0.07% invested in Eli Lilly and Company (NYSE:LLY). Moreover, Point72 Asset Mngmt L P has 0.23% invested in Eli Lilly and Company (NYSE:LLY) for 600,000 shares. Ontario – Canada-based Sun Life Fincl has invested 0.06% in Eli Lilly and Company (NYSE:LLY). Hightower Ltd Liability Corp accumulated 291,640 shares. Aldebaran Finance owns 5,950 shares. Woodley Farra Manion Portfolio Management holds 0.2% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 20,441 shares.

Since August 31, 2017, it had 0 insider buys, and 6 insider sales for $83.39 million activity. Another trade for 12,500 shares valued at $1.08 million was made by Simmons Jeffrey N on Monday, December 11.

Eli Lilly (NYSE:LLY) Receives a Downgrade

It appears that trading for shares of Eli Lilly (NYSE:LLY) will be interesting to watch today. Goldman Sachs lowered the stock from their past Buy rating to a more current Neutral.

Investors sentiment decreased to 0.89 in 2017 Q3. Its down 0.01, from 0.9 in 2017Q2. It fall, as 66 investors sold Eli Lilly and Company shares while 386 reduced holdings. 79 funds opened positions while 325 raised stakes. 827.83 million shares or 0.59% more from 823.00 million shares in 2017Q2 were reported.

Pinnacle Finance Prns invested in 37,083 shares. Moreover, Optimum Inv Advisors has 0.22% invested in Eli Lilly and Company (NYSE:LLY) for 7,560 shares. Amer Mgmt holds 300 shares. Great West Life Assurance Can, a Manitoba – Canada-based fund reported 993,282 shares. Winslow Mngmt Ltd has 1.76% invested in Eli Lilly and Company (NYSE:LLY) for 3.81M shares. Mitsubishi Ufj Tru & has invested 0.36% in Eli Lilly and Company (NYSE:LLY). Pinebridge Investments Lp has invested 0.27% of its portfolio in Eli Lilly and Company (NYSE:LLY). Bancorpsouth Inc accumulated 2,727 shares. Cornerstone Inv Prtnrs Limited Liability Corporation holds 0.05% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 27,278 shares. Moreover, Dimensional Fund Advisors Lp has 0.07% invested in Eli Lilly and Company (NYSE:LLY). Moreover, Point72 Asset Mngmt L P has 0.23% invested in Eli Lilly and Company (NYSE:LLY) for 600,000 shares. Ontario – Canada-based Sun Life Fincl has invested 0.06% in Eli Lilly and Company (NYSE:LLY). Hightower Ltd Liability Corp accumulated 291,640 shares. Aldebaran Finance owns 5,950 shares. Woodley Farra Manion Portfolio Management holds 0.2% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 20,441 shares.

Since August 31, 2017, it had 0 insider buys, and 6 insider sales for $83.39 million activity. Another trade for 12,500 shares valued at $1.08 million was made by Simmons Jeffrey N on Monday, December 11.

Eli Lilly and Company (NYSE:LLY) Ratings Coverage

Among 20 analysts covering Eli Lilly and Company (NYSE:LLY), 12 have Buy rating, 1 Sell and 7 Hold. Therefore 60% are positive. Eli Lilly and Company has $125 highest and $64 lowest target. $94.37’s average target is 9.99% above currents $85.8 stock price. Eli Lilly and Company had 90 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Eli Lilly and Company (NYSE:LLY) has “Buy” rating given on Tuesday, March 15 by Jefferies. The firm has “Outperform” rating by Credit Suisse given on Tuesday, December 8. Citigroup maintained Eli Lilly and Company (NYSE:LLY) on Friday, April 7 with “Buy” rating. The rating was upgraded by Barclays Capital on Tuesday, December 1 to “Overweight”. The firm has “Hold” rating by Goldman Sachs given on Tuesday, January 16. BMO Capital Markets maintained the stock with “Sell” rating in Wednesday, July 19 report. The firm earned “Buy” rating on Friday, September 18 by Jefferies. BMO Capital Markets downgraded it to “Market Perform” rating and $64 target in Friday, November 25 report. BMO Capital Markets maintained it with “Underperform” rating and $73 target in Tuesday, October 10 report. On Monday, December 7 the stock rating was upgraded by Deutsche Bank to “Buy”.

The stock increased 0.60% or $0.51 during the last trading session, reaching $85.8. About 78,479 shares traded. Eli Lilly and Company (NYSE:LLY) has risen 4.70% since January 17, 2017 and is uptrending. It has underperformed by 12.00% the S&P500.

Analysts await Eli Lilly and Company (NYSE:LLY) to report earnings on January, 30. They expect $1.08 EPS, up 13.68 % or $0.13 from last year’s $0.95 per share. LLY’s profit will be $1.13 billion for 19.86 P/E if the $1.08 EPS becomes a reality. After $1.05 actual EPS reported by Eli Lilly and Company for the previous quarter, Wall Street now forecasts 2.86 % EPS growth.

Eli Lilly and Company discovers, develops, makes, and markets pharmaceutical products worldwide. The company has market cap of $89.85 billion. It operates through two divisions, Human Pharmaceutical Products and Animal Health Products. It has a 40.84 P/E ratio. The firm offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Benzinga.com which released: “Argus Shares Eli Lilly’s Optimism, Upgrades To Buy” on January 05, 2018, also 247Wallst.com with their article: “Top Analyst Upgrades and Downgrades: Amazon, Boeing, Chesapeake Energy, Eli …” published on January 16, 2018, Streetinsider.com published: “Eli Lilly & Co. (LLY) Awards $5M Investment to PureTech Health Affiliate …” on December 19, 2017. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Fool.com and their article: “Eli Lilly & Co. at JP Morgan: 5 Things Investors Will Want to Know” published on January 10, 2018 as well as Fool.com‘s news article titled: “Is Eli Lilly and Company a Buy in 2018?” with publication date: January 17, 2018.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>